JP2017523781A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523781A5
JP2017523781A5 JP2017505552A JP2017505552A JP2017523781A5 JP 2017523781 A5 JP2017523781 A5 JP 2017523781A5 JP 2017505552 A JP2017505552 A JP 2017505552A JP 2017505552 A JP2017505552 A JP 2017505552A JP 2017523781 A5 JP2017523781 A5 JP 2017523781A5
Authority
JP
Japan
Prior art keywords
aptamer
nucleic acid
seq
dimer
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505552A
Other languages
English (en)
Japanese (ja)
Other versions
JP6680760B2 (ja
JP2017523781A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043162 external-priority patent/WO2016019270A1/en
Publication of JP2017523781A publication Critical patent/JP2017523781A/ja
Publication of JP2017523781A5 publication Critical patent/JP2017523781A5/ja
Application granted granted Critical
Publication of JP6680760B2 publication Critical patent/JP6680760B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505552A 2014-07-31 2015-07-31 アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用 Expired - Fee Related JP6680760B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031427P 2014-07-31 2014-07-31
US62/031,427 2014-07-31
PCT/US2015/043162 WO2016019270A1 (en) 2014-07-31 2015-07-31 An antagonistic pd-1 aptamer and its applications in cancer therapy related applications

Publications (3)

Publication Number Publication Date
JP2017523781A JP2017523781A (ja) 2017-08-24
JP2017523781A5 true JP2017523781A5 (https=) 2018-09-13
JP6680760B2 JP6680760B2 (ja) 2020-04-15

Family

ID=55218360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505552A Expired - Fee Related JP6680760B2 (ja) 2014-07-31 2015-07-31 アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用

Country Status (8)

Country Link
US (1) US10329570B2 (https=)
EP (1) EP3174985A4 (https=)
JP (1) JP6680760B2 (https=)
KR (1) KR20170055474A (https=)
CN (1) CN107002083A (https=)
CA (1) CA2956718A1 (https=)
TW (1) TWI703214B (https=)
WO (1) WO2016019270A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US11219635B2 (en) 2016-02-19 2022-01-11 City Of Hope Bi-specific aptamer
EP3509700A1 (en) * 2016-09-06 2019-07-17 The Methodist Hospital System Pd-1 specific aptamers
EP3512526A4 (en) * 2016-09-16 2020-05-27 Duke University VON WILLEBRAND FACTOR (VWF) TARGETING AGENTS AND METHODS OF USE
CN107794267B (zh) * 2017-03-14 2021-03-26 湖南大学 一种靶向pd1-pdl1的双特异性核酸适体及其衍生物
KR20200068647A (ko) 2017-08-11 2020-06-15 시티 오브 호프 트랜스페린 수용체 (TfR)에 대한 RNA 앱타머
US11007211B2 (en) * 2018-01-07 2021-05-18 City Of Hope CCR7 aptamers and uses thereof
EP3683310A1 (en) 2019-01-21 2020-07-22 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer and use of the aptamer in the diagnosis and treatment of cancer
CN111154765B (zh) * 2019-12-30 2023-08-01 广西医科大学 T细胞免疫检查点pd-1的适配体筛选、鉴定方法及抗肿瘤应用
MX2022010955A (es) 2020-03-03 2022-10-07 Array Biopharma Inc Metodos para tratar el cancer usando (r)-n-(3-fluoro-4-((3- ((1-hidroxipropan-2-il)amino)-1h-pirazolo[3,4-b]piridin-4-il)oxi) fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetrahidro pirimidin-5-carboxamida.
CN111593053B (zh) * 2020-05-27 2022-02-15 武汉大学 识别人程序性死亡受体1的dna适配体及方法和应用
EP4419112A4 (en) * 2021-10-22 2025-08-27 Ohio State Innovation Foundation IMMUNOTHERAPY FOR CANCER TREATMENT

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU1959897A (en) * 1996-02-22 1997-09-10 Board Of Trustees Of Michigan State University Gene specific universal mammalian sequence-tagged sites
EP1268856A2 (de) * 2000-04-07 2003-01-02 Epigenomics AG Detektion von snp's und cytosin-methylierungen
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20040180360A1 (en) * 2002-11-21 2004-09-16 Charles Wilson Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2007525177A (ja) * 2003-04-21 2007-09-06 アーケミックス コーポレイション 血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用
MEP0208A (xx) * 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
JP2009536222A (ja) * 2006-05-05 2009-10-08 アイシス ファーマシューティカルズ, インコーポレーテッド Pcsk9の発現を調節するための化合物および方法
EP2406396A2 (en) * 2009-03-12 2012-01-18 Brainco Biopharma, S.L. A genotyping tool for improving the prognostic and clinical management of ms patients
WO2010144295A1 (en) * 2009-06-09 2010-12-16 University Of Miami Aptamer-targeted costimulatory ligand aptamer
EP2354247A1 (en) * 2010-02-11 2011-08-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for typing a sample for rheumatoid arthritis or spondyloarthritis
US20140148503A1 (en) * 2011-07-20 2014-05-29 University Of Iowa Research Foundation Nucleic acid aptamers
CN104145020B (zh) * 2012-02-16 2020-06-02 先正达参股股份有限公司 工程化的杀有害生物蛋白质
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
EA201492122A1 (ru) * 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии utrn
EP4170031A1 (en) * 2012-10-23 2023-04-26 Caris Science, Inc. Aptamers and uses thereof
JP2015536952A (ja) * 2012-11-05 2015-12-24 プロナイ セラピューティクス インコーポレイテッド オリゴヌクレオチド癌療法の投薬および実施
WO2014082083A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
CA2954791C (en) * 2014-07-14 2025-11-18 The Regents Of The University Of California CRISPR/CAS TRANSCRIPTIONAL MODULATION

Similar Documents

Publication Publication Date Title
JP2017523781A5 (https=)
JP2018503668A5 (https=)
Luo et al. Biodegradable multiblock poly [N-(2-hydroxypropyl) methacrylamide] via reversible addition− fragmentation chain transfer polymerization and click chemistry
Li et al. Current drug research on PEGylation with small molecular agents
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
JP2016521688A5 (https=)
CN102920649B (zh) 载药纳米胶束及其制备方法和应用
JP2013515745A5 (https=)
JP2019513118A5 (https=)
JP2014521661A5 (https=)
JP2018015005A5 (https=)
JP2012255007A5 (https=)
Ji et al. Development of self-assembled multi-arm polyrotaxanes nanocarriers for systemic plasmid delivery in vivo
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
JP2016153410A5 (https=)
JP2016502515A5 (https=)
JP2014526881A5 (https=)
JP2015519313A5 (https=)
JP2014520120A5 (https=)
JP2019531093A5 (https=)
JP2012509902A5 (https=)
JP2017528444A5 (https=)
MX2021006989A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
JP2017501130A5 (https=)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения